Big Pharma Split Stock Probability Of Bankruptcy
| PRM Stock | CAD 13.12 0.01 0.08% |
Big | Probability Of Bankruptcy |
Big Pharma Split Company odds of distress Analysis
Big Pharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Big Pharma Probability Of Bankruptcy | Over 81% |
Most of Big Pharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Big Pharma Split is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Big Pharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Big Pharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Big Pharma Split financial health.
Big Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Big Pharma is extremely important. It helps to project a fair market value of Big Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Big Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Big Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Big Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Big Pharma Split has a Probability Of Bankruptcy of 81%. This is 62.23% higher than that of the Capital Markets sector and 101.49% higher than that of the Financials industry. The probability of bankruptcy for all Canada stocks is 103.36% lower than that of the firm.
Big Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Big Pharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Big Pharma could also be used in its relative valuation, which is a method of valuing Big Pharma by comparing valuation metrics of similar companies.Big Pharma is currently under evaluation in probability of bankruptcy category among its peers.
Big Pharma Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Return On Assets | 0.17 | 0.0116 | 0.13 | 0.0805 | (0.005264) | (0.005001) | |
| Asset Turnover | 0.0896 | 0.0257 | 0.14 | 0.0949 | 0.0117 | 0.0112 | |
| Gross Profit Margin | 0.9 | 0.53 | 0.93 | 0.89 | 1.03 | 0.7 | |
| Net Debt | 10.0M | 9.1M | 13.4M | 9.0M | 10.1M | 8.7M | |
| Total Current Liabilities | 10.9M | 213.2K | 339.0K | 347.8K | 11.1M | 5.9M | |
| Non Current Liabilities Total | 10.9M | 9.7M | 15.4M | 347.8K | 10.7M | 7.5M | |
| Total Assets | 27.2M | 22.9M | 37.8M | 39.1M | 26.5M | 34.5M | |
| Total Current Assets | 27.2M | 335.2K | 1.5M | 14.8M | 999.5K | 949.6K | |
| Total Cash From Operating Activities | 8.7M | 4.3M | (9.0M) | 1.1M | 11.9M | 12.5M |
Big Fundamentals
| Return On Equity | -0.0363 | |||
| Return On Asset | -0.0069 | |||
| Profit Margin | (2.01) % | |||
| Operating Margin | 0.51 % | |||
| Current Valuation | (9.41 M) | |||
| Shares Outstanding | 1.13 M | |||
| Number Of Shares Shorted | 100 | |||
| Price To Book | 0.94 X | |||
| Price To Sales | 46.24 X | |||
| Revenue | 311.76 K | |||
| Gross Profit | 5.56 M | |||
| EBITDA | (139.68 K) | |||
| Net Income | (645.35 K) | |||
| Total Debt | 10.3 M | |||
| Book Value Per Share | 13.99 X | |||
| Cash Flow From Operations | 11.86 M | |||
| Short Ratio | 1.19 X | |||
| Earnings Per Share | 0.99 X | |||
| Target Price | 2.0 | |||
| Beta | 0.88 | |||
| Market Capitalization | 14.83 M | |||
| Total Asset | 26.53 M | |||
| Annual Yield | 0.09 % | |||
| Net Asset | 26.53 M | |||
| Last Dividend Paid | 1.24 |
About Big Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Big Pharma Split's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Big Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Big Pharma Split based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Big Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Big Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Big Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with Big Stock
Moving against Big Stock
The ability to find closely correlated positions to Big Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Big Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Big Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Big Pharma Split to buy it.
The correlation of Big Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Big Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Big Pharma Split moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Big Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Big Stock
Big Pharma financial ratios help investors to determine whether Big Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Big with respect to the benefits of owning Big Pharma security.